Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

In a study of patients with atopic dermatitis, tralokinumab was effective and safe in elderly patients and those with severe comorbidities.

The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.

Your daily dose of the clinical news you may have missed.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.

Your daily dose of the clinical news you may have missed.

In a study of patients with CHE, 75.5% of participants totally or almost agreed that topical corticosteroids cause damage to skin.

Your daily dose of the clinical news you may have missed.

The “Do It For You & Them” campaign focuses on the impact that virus has on day-to-day lives.